Edition:
United States

AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

3.40USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$3.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
282,395
52-wk High
$11.50
52-wk Low
$2.60

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Inc announces proposed public offering of common shares
Tuesday, 8 Dec 2015 04:15pm EST 

Aeterna Zentaris Inc:Has commenced an underwritten public offering of common shares and warrants to purchase common shares.  Full Article

Aeterna Zentaris Inc announces departure of CFO
Monday, 12 Oct 2015 08:26am EDT 

Aeterna Zentaris Inc:Says departure of Dennis Turpin, the Company's former Senior Vice President, Chief Financial Officer.Says Turpin, Chief Accounting Officer, will take responsibility for all internal and external financial reporting on an interim basis while comapny conducts an external search for a permanent CFO.  Full Article

Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen(tm) in AGHD Meets EMA's Study-Design Expectations
Tuesday, 26 May 2015 07:30am EDT 

Aeterna Zentaris Inc:Says it has received written scientific advice from the European Medicines Agency ("EMA") regarding the further development plan, including the study design, for the new confirmatory Phase 3 clinical study of Macrilen.Says as a result of the advice, the company believes that the confirmatory Phase 3 study that was discussed with the U.S. Food & Drug Administration ("FDA") last March, meets the EMA's study-design expectations.Says believe that completion of the confirmatory phase 3 study and the qt study will take 15 to 18 months.SAYS ema proposes that co consider additional aspects regarding demonstration of reproducibility of a diagnosis made using macrilen.  Full Article

Aeterna Zentaris Inc announces plans to initiate Phase 3 study of Macrilen in AGHD following successful meeting with FDA
Monday, 13 Apr 2015 07:30am EDT 

Aeterna Zentaris Inc:Says plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate efficacy of Macrilen (macimorelin), novel orally-active ghrelin agonist.For use in evaluating adult growth hormone deficiency (AGHD), as well as dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization.Says decision follows positive and helpful meeting with U.S. FDA regarding its New Drug Application for Macrilen.Company requested meeting to gain clarity on approval deficiencies described in Complete Response Letter (CRL) company received on Nov. 6, 2014.  Full Article

Aeterna Zentaris announces closing of $37 million public offering of common shares and warrants
Wednesday, 11 Mar 2015 10:15am EDT 

Aeterna Zentaris:Says closing of public offering of 59,677,420 units generating net proceeds of about $34.5 mln, with each unit consisting of one common share, 0.75 of Series A warrant to purchase one common share, and 0.50 of Series B warrant to purchase one common share, at purchase price of $0.62 per unit.Says the Series A warrants are exercisable immediately and expire five years following issuance at an exercise price of $0.81 per share.Says Series B warrants are exercisable immediately and expire 18 months following issuance at an exercise price of $0.81 per share.Says pre-funded Series C warrants are exercisable immediately and expire five years following issuance.Intends to use net proceeds from Offering to make the $5.7 mln payment to the holders of warrants in connection with warrant amendment agreements described above, to continue to fund ongoing drug development activities.Also uses for the potential addition of commercialized products to the Company's pipeline, and for general corporate purposes, for working capital and to fund negative cash flow.  Full Article

Aeterna Zentaris announces pricing of $37 million public offering of common shares and warrants
Friday, 6 Mar 2015 08:30am EST 

Aeterna Zentaris Inc:Pricing of its previously announced public offering 59,677,420 units.Each Unit consists of one common share, 0.75 of a Series A warrant to purchase one common share, and 0.50 of a Series B warrant to purchase one common share, at purchase price of US$0.62 per Unit.Offering is expected to close on or about March 11.Net proceeds from the Offering are expected to be about $34.5 million, after deducting underwriting commissions and other expenses related to the Offering.Company intends to use the net proceeds from the Offering to make the $5.7 million payment to the holders of warrants in connection with the warrant amendment agreements described above.To continue to fund ongoing drug development activities, for the potential addition of commercialized products to the Company's pipeline, and for general corporate purposes, for working capital and to fund negative cash flow.Canaccord Genuity Inc. is acting as the sole book-running manager for the Offering. Maxim Group LLC, H.C. Wainwright & Co., LLC and Roth Capital Partners acted as co-managers for the Offering.  Full Article

Aeterna Zentaris Inc announces proposed public offering of common shares and warrants
Thursday, 5 Mar 2015 04:08pm EST 

Aeterna Zentaris Inc:Has commenced an underwritten public offering of units.Units will consist of common shares, Series A warrants to purchase common shares and Series B warrants to purchase common shares.Canaccord Genuity Inc. is acting as sole manager for proposed offering.Proposed offering is subject to customary conditions, including approval of The NASDAQ Stock Market (NASDAQ) and Toronto Stock Exchange (TSX), and there can be no assurance as to whether or when the proposed offering may be completed, or as to actual size or terms of offering.Company has no intention of listing either series of warrants on NASDAQ or TSX.  Full Article

Ergomed plc announces co-development partner news from Aeterna Zentaris
Monday, 8 Dec 2014 02:00am EST 

Ergomed plc:Says that Aeterna Zentaris has signed an exclusive licence and technology transfer agreement with Sinopharm A-Think.For Chinese, Hong Kong and Macau markets for zoptarelin doxorubicin which is in Phase 3 development for treating endometrial cancer.Says Sinopharm A-Think will be responsible for development, production, registration and commercialization of product in these markets.Sinopharm A-Think will be responsible for development, production, registration and commercialization of product in these markets.  Full Article

Aeterna Zentaris and Sinopharm A-Think sign master collaboration agreement for Zoptarelin Doxorubicin in China
Monday, 1 Dec 2014 07:30am EST 

Aeterna Zentaris Inc and Sinopharm A-Think Pharmaceuticals Co., Ltd:Signs license and technology transfer agreement, for the lead anti-cancer compound, zoptarelin doxorubicin, for the initial indication of endometrial cancer, for the Chinese, Hong Kong and Macau markets.Under the terms of the Master Collaboration Agreement, Aeterna Zentaris will be entitled to receive a non?refundable $1 million fee for the transfer of the Company's technology for zoptarelin doxorubicin to SinopharmA-Think.  Full Article

BRIEF-Aeterna zentaris Q3 loss per share $0.61

* Aeterna Zentaris - believe have funds necessary to complete two pivotal clinical trials, to report top-line results on both, to file a nda for macrilen in first half of 2017